Navigation Links
Candela Receives Registration Approval to Market Its Best-in-Class GentleMax and Alex TriVantage Lasers in China
Date:2/10/2010

WAYLAND, Mass., Feb. 10 /PRNewswire/ -- Candela Corporation, a Syneron company (Nasdaq: ELOS), announced today that the SFDA (State Food and Drug Administration) of China has approved the Alex TriVantage® multi-wavelength, Q-switched laser system and the GentleMax® multiple wavelength workstation for sale throughout the People's Republic of China, including Hong Kong. The receipt of the SFDA Certificates will allow Candela to begin the sales process and launch official marketing programs for these products, creating a host of new market opportunities.

The unique Q-switched Laser-Pumped-Laser (LPL) technology of the Alex TriVantage laser provides 755-nm, 532-nm and 1064-nm output wavelengths, making Alex TriVantage extremely versatile. The addition of a long-pulse mode at 755 nm offers advanced treatments for a wider variety of pigmented lesions (many unique to Asian skin) without long-term side effects. Beyond the treatment of benign pigmented lesions and the removal of multi-color tattoo inks, Alex TriVantage enhances the results of many skin rejuvenation treatments, making it an ideal system for optimizing fractional and other rejuvenation treatment results. 

By integrating two of aesthetic laser medicine's leading devices, the GentleLASE and GentleYAG, into a configurable, upgradeable workstation, the GentleMax has made treatment for a wider range of patient concerns more readily available. The GentleMax laser system features both 755-nm and 1064-nm wavelengths and may be used to provide permanent hair reduction on all skin types and tanned skin as well as the treatment of vascular and pigmented lesions, wrinkle reduction and skin tightening. With GentleMax, it is now possible for one device to do the work of two or more.

"The Alex TriVantage is our first Q-switched alexandrite laser to be approved in China," said Syneron Chief Executive Officer Louis P. Scafuri. "With its unique Laser-Pumped-Laser (LPL) technology and GentleMax's multiple wavelengths and uses, a greater number of physicians will be able to offer a wider variety of services for conditions with fewer devices. Moreover, this approval enables us to offer a more complete range of highly effective aesthetic solutions in the world's largest market."   

For more information on the GentleMax and Alex TriVantage lasers, visit www.candelalaser.com

About Candela

Candela is a wholly-owned subsidiary of Syneron Medical Ltd. (NASDAQ: ELOS), the global leader of aesthetic devices offering the industry's most comprehensive product portfolio and worldwide distribution footprint. The Candela brand supports Syneron's line of aesthetic therapies for the face and body with four decades of industry-leading scientific expertise and innovative aesthetic laser technologies. Syneron distributes and supports its products in 86 countries with offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong. Additional information can be found at www.syneron.com.

SOURCE Candela Corporation

RELATED LINKS
http://www.candelalaser.com
http://www.syneron.com

'/>"/>

SOURCE Candela Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... WOONSOCKET, R.I. , Feb. 10, 2016  CVS ... vaccines to people living in Santa Clara ... of Meningitis B on the Santa Clara University campus. ... vaccines available to protect patients against the disease. Students ... are encouraged to get vaccinated. In addition, anyone who ...
(Date:2/10/2016)... Feb. 10, 2016  Oxis International Inc. (OTC/QB: OXIS) ... was described as a "clinical trial triumph" after one ... into complete cancer remission. Daniel Vallera ... Masonic Cancer Center. --> Daniel Vallera ... Masonic Cancer Center. --> An article ...
(Date:2/10/2016)... 2016  LexisNexis® Risk Solutions, a leading provider ... launch of LexisNexis Provider Performance Monitor , ... and optimize the quality and efficiency of provider ... scores. By measuring provider performance through Provider Performance ... better outcomes, improve the patient experience and reduce ...
Breaking Medicine Technology:
(Date:2/10/2016)... Calif. (PRWEB) , ... February 10, 2016 , ... ... Water Brand. There were three leading bottled water brand owners that topped the list ... that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... bring together more than 200 of the country’s top healthcare executives to share ... “The true benefit of the Forum is the provider-centric perspective, experience, expertise and ...
(Date:2/10/2016)... ... ... Armune BioScience signed a definitive agreement with ARCpoint Labs ... country. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA blood ... exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny to ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... the Ohio Safety Congress and Expo event March 9-11, 2016. Hosted by Ohio's ... Convention Center. , As the longest running and largest worker's compensation event ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... Drive, Jacksonville, FL 32224, February 26th: Amateur & Professional Divisions - Time: ... Time: 7:00pm – 10:00pm | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org ...
Breaking Medicine News(10 mins):